No decrease in susceptibility to NVC-422 in multiple-passage studies with methicillin-resistant Staphylococcus aureus, S. aureus, Pseudomonas aeruginosa, and Escherichia coli

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 5, 2012, Pages 2753-2755

  D'Lima, Louisa ^a   Friedman, Lisa ^a   Wang, Lu ^a   Xu, Ping ^a   Anderson, Mark ^a   Debabov, Dmitri ^a  

^a NovaBay Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CIPROFLOXACIN; FUSIDIC ACID; N,N DICHLORO 2,2 DIMETHYLTAURINE; NVC 422; PSEUDOMONIC ACID; RETAPAMULIN; UNCLASSIFIED DRUG;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; DRUG SAFETY; DRUG STABILITY; ESCHERICHIA COLI; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IMPETIGO; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BICYCLO COMPOUNDS, HETEROCYCLIC; CIPROFLOXACIN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ESCHERICHIA COLI; FUSIDIC ACID; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; TAURINE;

EID: 84860178045     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05985-11     Document Type: Article

References (22)

1. Archer G. 1998. Staphylococcus aureus: a well-armed pathogen. Clin. Infect. Dis. 26:1179 -1181.
2. Chen HJ, et al. 2010. Fusidic acid resistance determinants in Staphylococcus aureus clinical isolates. Antimicrob. Agents Chemother. 54:4985-4991.
3. Clark C, McGhee P, Appelbaum PC, Kosowska-Shick K. 2011. Multistep resistance development studies of ceftaroline in gram-positive and -negative bacteria. Antimicrob. Agents Chemother. 55:2344 -2351.
4. Clinical and Laboratory Standards Institute. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A6. Clinical and Laboratory Standards Institute, Wayne, PA.
5. Davies TA, Pankuch GA, Dewasse BE, Jacobs MR, Appelbaum PC. 1999. In vitro development of resistance to five quinolones and amoxicillin- claulanate in Streptococcus pneumoniae. Antimicrob. Agents Chemother. 42:1177-1182. (Pubitemid 29214743)
6. Farrell DJ, Robbins M, Rhys-Williams W, Love WG. 2011. Investigation of the potential for mutational resistance to XF-73, retapamulin, mupirocin, fusidic Acid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus isolates during a 55-passage study. Antimicrob. Agents Chemother. 55:1177-1181.
7. Friedman L, Alder JD, Silverman JA. 2006. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob. Agents Chemother. 50:2137-2145. (Pubitemid 43807536)
8. Gentry DR, et al. 2008. Genetic characterization of Vga ABC proteins conferring reduced susceptibility to pleuromutilins in Staphylococcus aureus. Antimicrob. Agents Chemother. 52:4507- 4509.
9. Gilbert DN, et al. 2001. Phenotypic resistance of Staphylococcus aureus, selected Enterobacteriaceae, and Pseudomonas aeruginosa after single and multiple in vitro exposures to ciprofloxacin, levofloxacin, and trovafloxacin. Antimicrob. Agents Chemother. 45:883- 892.
10. Goossens H, Ferech M, Vander Stichele R, Elseviers M. 2005. Outpatient antibiotic use in Europe and association with resistance: a crossnational database study. Lancet 365:579 -587.
11. Iovino SM, et al. 2011. NVC-422 topical gel for the treatment of impetigo. Int. J. Clin. Exp. Pathol. 4:587-595.
12. Kaper JB, Nataro JP, Mobley HL. 2004. Pathogenic Escherichia coli. Nat. Rev. Microbiol. 2:123-140. (Pubitemid 39490066)
13. Kosowska-Shick K, et al. 2006. Single- and multistep resistance selection studies on the activity of retapamulin compared to other agents against Staphylococcus aureus and Streptococcus pyogenes. Antimicrob. Agents Chemother. 50:765-769. (Pubitemid 43190997)
14. Levy SB. 2000. Antibiotic and antiseptic resistance: impact on public health. Pediatr. Infect. Dis. J. 19:S120 -S122.
15. Martinez JL, Baquero F, Andersson DI. 2011. Beyond serial passages: new methods for predicting the emergence of resistance to novel antibiotics. Curr. Opin. Pharmacol. 11:439-445.
16. Patel JB, Gorwitz RJ, Jernigan JA. 2009. Mupirocin resistance. Clin. Infect. Dis. 49:935-941.
17. Poole K. 2011. Pseudomonas aeruginosa: resistance to the max. Front. Microbiol. 2:1-13.
18. Shawar R, et al. 2009. Topical retapamulin in the management of infected traumatic skin lesions. Ther. Clin. Risk Manag. 5:41- 49.
19. Traczewski MM, Brown SD. 2008. Proposed MIC and disk diffusion microbiological cutoffs and spectrum of activity of retapamulin, a novel topical antimicrobial agent. Antimicrob. Agents Chemother. 51:3880-3886.
20. Wang L, Khosrovi B, Najafi R. 2008. N-Chloro-2,2-dimethyltaurines: stable homologues of N-chlorotaurines. Tetrahedron Lett. 49:2193-2195.
21. Wang L, et al. 2011. Chemical characterization and biological properties of NVC-422, a novel, stable N-chlorotaurine analog. Antimicrob. Agents Chemother. 55:2688 -2692.
22. Yoon J, et al. 2011. Virucidal mechanism of action of NVC-422, a novel antimicrobial drug for the treatment of adenoviral conjunctivitis. Antiviral Res. 92:470-478.